| ADTX 0.01 127.27% | GDC 0.0181 -15.02% | SOXS 3.59 -19.51% | GPUS 0.359 -9.78% | SRXH 0.1245 -37.59% | BITO 8.56 -1.95% | TZA 4.02 -5.85% | SPCX 185 -3.56% | MRVL 310.58 7.27% | CDT 1.02 47.19% | NVDA 210.69 2.95% | INTC 133.99 10.64% | WKSP 0.7379 23.33% | INLF 0.1566 -64.20% | NOK 13.49 -2.46% | AAL 15.99 3.70% | AZTR 0.1717 -15.42% | CAST 8.07 56.70% | CRVO 4.24 11.29% | NFLX 77.38 0.55% | AMC 2.83 6.39% | QS 8.04 16.52% | FLEX 147.61 3.13% | GRAB 3.57 3.48% | SOFI 17.91 2.81% | YYGH 0.0803 -37.70% | AAPL 298.01 0.70% | ATPC 3.88 42.12% | RKLB 107.24 -0.69% | BAC 56.2 -0.58% | LNKS 2.68 67.50% | SMCI 30.66 10.37% | PFE 25.22 -2.70% | SPY 746.74 0.78% | RIG 5.31 -4.84% | AMZN 244.39 2.90% | PLUG 2.85 7.55% | CRWV 117.95 2.38% | TSLL 13.16 1.86% | ONDS 9.27 1.64% | CMCSA 22.43 -1.15% | MU 1133.99 8.70% | TQQQ 82.87 6.87% | BFLY 8.9 55.87% | NVD 4.75 -5.57% | SQQQ 36.75 -7.01% | MSFT 379.4 0.13% | CTSH 43.7 -10.49% | WPRT 2.26 21.51% | T 22.01 -1.92%

Citigroup Upgrades Albemarle (NYSE: ALB) to Buy Amidst Financial Strengthening

On June 18, 2026, investment firm Citigroup upgraded its rating for Albemarle (NYSE: ALB) from Neutral to Buy. Albemarle is a global specialty chemicals company and a leading producer of lithium, a key component for electric vehicle batteries. At the time of the upgrade, Albemarle's stock price was $166.56.

The upgrade reflects Albemarle's recent actions to strengthen its financial position. Albemarle successfully paid down $1.3 billion of its debt. This strategic move is expected to lower its annual interest expenses by approximately $60 million, significantly improving its profitability and making the company more financially stable.

These improvements were funded by selling its stake in Ketjen and its interest in the Eurecat joint venture, which generated $670 million. As a result, Albemarle's long-term debt fell to $1.81 billion from $3.12 billion at the end of 2025. The company now holds about $2.7 billion in liquidity.

Citigroup's positive view is shared by other analysts. As highlighted by Zacks Investment Research, Albemarle holds an average brokerage recommendation of 1.88 on a scale of 1 (Strong Buy) to 5 (Strong Sell). Out of 25 brokerage firms, 13 rate the stock a Strong Buy and two rate it a Buy.

Despite the stock falling 23.6% over the past four weeks, some analysts see a potential for stock recovery. As highlighted by Zacks Investment Research, this drop has pushed the stock into what is technically considered "oversold" territory. This term suggests a stock's price may have fallen too quickly and could be due for a rebound.

Published on: June 18, 2026